syringoma/erythema

A dermoscopy of linear unilateral syringoma has never been described in the English literature. The authors report the case to elucidate the dermoscopic features of syringoma. Clinical, dermoscopic and pathological features of a 38-year-old Japanese female case of linear unilateral syringoma on the

BACKGROUND The 1,444 nm wavelength is also well absorbed in water making it a possible setting for treatment of cystic lesions such as eccrine hydrocystomas and syringomas. OBJECTIVE The authors aimed to investigate the efficacy of an externally used 1,444 nm neodymium-doped yttrium aluminum garnet

Syringomas are benign tumors of eccrine origin that occur primarily in the lower eyelid region of females. Since they do not involute and are typically refractory to conventional forms of therapy, they may grow to become considerable, chronic cosmetic and functional deficits. The current study

BACKGROUND Syringomas usually develop in women as multiple skin-colored papules primarily seen on the periocular regions and cheeks. They can cause cosmetic problems and lead to poor self-esteem. Though several treatment modalities have been established, such as excision, electro/cryosurgery,

BACKGROUND Syringomas are relatively common benign adnexal tumors, predominantly developing in middle-aged women. They frequently involve the periorbital areas and cause cosmetic problems. Up to now, various treatment modalities such as electrodesiccation, laser ablation, cryosurgery, and some

BACKGROUND Syringomas are benign tumors of eccrine origin most commonly found in the periorbital area. Previously reported treatments for syringomas include excision, electrodesiccation and curettage, dermabrasion, and carbon dioxide (CO2) laser resurfacing. The ideal treatment of syringomas should

BACKGROUND Management of periorbital syringomas is problematic and avoided by many inexperienced physicians. The medical literature presently prefers CO(2) laser resurfacing to many other modalities, but the subject of electrosurgery has not been well explored. OBJECTIVE To evaluate the clinical

Cutaneous reactions to imatinib are common and occur in 9.5% to 69% of patients depending on the series reported. Maculopapular eruptions, erythematous eruptions, edema, and periorbital edema are the most common adverse events observed. Imatinib can also induce severe skin eruptions and generalized